Atara Biotherapeutic announced its recent submission of an Investigational New Drug IND application to the U.S. Food and Drug Administration FDA for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus SLE with kidney involvement upus nephritis . “Despite therapeutic advances, there remains high unmet need in lupus nephritis, where standard of care and approved therapies have limited efficacy that often rely on multi-year, if not lifelong immune suppression,” said Rajani Dinavahi, Chief Medical Officer at Atara. “We are dedicated to advancing medical breakthroughs with innovative cell therapies that truly make a difference. We look forward to working with the FDA to initiate this study and advance ATA3219 into the clinic to potentially bring a new disease-modifying option for patients suffering from this chronic disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATRA:
- Biotech Alert: Searches spiking for these stocks today
- Atara Biotherapeutics, Pierre Fabre announce publication of ALLELE data
- Atara Biotherapeutics’ tabelecleucel meets primary endpoint in Phase 3 study
- Atara Biotherapeutics sells 27.272M shares at 55c in registered direct offering
- Atara Biotherapeutics announces $15M registered direct offering